Prolonged TNFα exposure is known to impair T cell responses (namely TCR-induced proliferation and cytokine production) by attenuating T cell receptor signaling [44,45], and anti-TNF therapy in patients with psoriasis and inflammatory bowel disease results in improved responses to TCR stimulation ex vivo [59]. This evidence concerns the gene TBXT and inflammatory bowel disease.